Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003690 · ClinicalTrials.gov registry record · Phase 1

Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target

NCT00003690: Completed Phase 1 study, sponsored by Mayo Clinic.

NCT00003690 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003690, a Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of flavopiridol plus cisplatin or carboplatin in treating patients who have advanced solid tumors.

Interventions

  • DRUG cisplatin
  • DRUG carboplatin
  • DRUG alvocidib

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 1998-12
Est. Completion 2003-09
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT00003690

The ClinicalTrials.gov registry entry for NCT00003690 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.

NCT00003690 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00003690 about?

NCT00003690 is a clinical study titled "Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of flavopiridol plus cisplatin or carboplatin in treating patients who ha...

What is the current status of trial NCT00003690?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 1998-12. Estimated completion is 2003-09.

What interventions are being tested in trial NCT00003690?

The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), alvocidib (DRUG).

Who is sponsoring clinical trial NCT00003690?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.